Robert Hayes

Dr Robert Hayes was Head of Biologics at multinational biopharmaceutical company Amgen (NASDAQ:AMGN) and was responsible for the leadership, strategic direction and operational management of the company’s biologics preclinical discovery and biotherapeutics pipeline. This included bioreagent generation, large molecule lead identification, biologics optimization, and the transition to upstream process development and manufacturing. Prior to Amgen, Dr Hayes spent seven years as vice president & venture leader of a biotech company within Janssen R&D that focused on developing and exploiting small alternative scaffold proteins. He was also senior director of Protein Engineering at Johnson and Johnson, one of the world's largest healthcare companies, for over three years. With over 20 years’ experience in biotech start-ups and large pharmaceutical companies, Dr Hayes also has significant experience in forming partnerships between biotech companies and university partners to advance the development and application of novel therapeutic platforms. Dr Hayes holds a PhD from Imperial College London, where he was the Royal College of Science Scholar and a Royal Society University Research Fellow. He also completed postdoctoral research at Imperial and University California at Berkeley.
Bio last updated 22 Apr 2017

Article Timeline

Access to our data for Robert Hayes is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Robert Hayes is linked to 1 organisation which is included in 1 list - Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 30/04/18

1 year TSR5 year TSR
145thFamily Zone Cyber Safety79%0%
408thKatana Capital6%4%
469thMejority Capital-1%-10%
721 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar


Chief Scientific Officer, Non-Executive Director (April-June 2017)
Year started and most recent title

Share Transactions

$25k Issued
Total value as at the date of the transaction
Source: Morningstar


121st↓Katana Capital$2.4m
123rd↓Mejority Capital$2.3m
124th↑Family Zone Cyber Safety$2.3m
238 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer